Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib Combined With Bevacizumab in EGFR Exon 20 Insertion NSCLC
NCT04974879Phase 2Unknown
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Progression free survival at 18 months. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04974879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974879.